New drug aims to speed platelet recovery in blood cancer transplants
NCT ID NCT07321626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called romiplostim N01 in 130 blood cancer patients receiving a stem cell transplant from a half-matched donor. The drug is given weekly for up to 4 weeks to help platelets recover faster, reducing the need for transfusions and bleeding risk. Half the patients get the drug, half get standard care, and researchers compare how quickly platelets return to safe levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Romiplostim N01 (a drug that boosts platelet production)
What this could lead to
If it works, this could help blood cancer patients recover platelets faster after a stem cell transplant, lowering the risk of dangerous bleeding.
What could go wrong
This is an early phase 1 trial with only 130 participants, so results may not apply to everyone. The drug could cause side effects like blood clots or not work better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••